← Back to Search

Virus Therapy

Convalescent Plasma for COVID-19

Phase 2

Waitlist Available

Research Sponsored by University of New Mexico

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 0,1,3,7 and 14

Awards & highlights

Study Summary

This trial is testing whether an experimental treatment, convalescent plasma, can help people with COVID-19. The treatment will be given to people who are hospitalized and researchers will monitor how well it works.

Eligible Conditions

COVID-19
Coronavirus

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 0,1,3,7 and 14

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 0,1,3,7 and 14

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0,1,3,7 and 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

NAb Dose Titer in the Convalescent Plasma (CP), Pre-treatment, and Day One in Hospitalized Patients With Documented COVID-19 Infection

Secondary outcome measures

Number of Participants With Clearance of Viral Shedding of SARS CoV-2 in Nasopharyngeal Samples

Number of Participants With Rapid Deterioration as Evidenced by Increase in Ordinal Score

Side effects data

From 2021 Phase 3 trial • 511 Patients • NCT04355767

12%

Pneumonia

Infusion related reaction

Dyspnea

Hypoxia

Fatigue

Pulmonary embolism

Chest pain

Flank pain

Migraine

Dehydration

Acute respiratory failure

Vomiting

Dizziness

100%

80%

60%

40%

20%

Study treatment Arm

Convalescent Plasma

Placebo

Trial Design

1Treatment groups

Experimental Treatment

Group I: Convalescent PlasmaExperimental Treatment1 Intervention

The investigational product is anti-SARS-CoV-2 convalescent plasma obtained from former patients identified as having recovered from COVID-19 and obtained by Vitalant from local and national donors following national blood donation guidelines. All subjects receive the convalescent plasma.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

COVID-19 convalescent plasma

Not yet FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of New MexicoLead Sponsor

372 Previous Clinical Trials

3,528,777 Total Patients Enrolled

6 Trials studying COVID-19

2,280 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Convalescent Plasma been tested in previous clinical research?

"Presently, there are 4 clinical trials examining the efficacy of Convalescent Plasma. None have yet entered Phase 3 and most locations running these experiments are in Bonheiden, Brabant Wallon with a total of 21 sites overall."

Answered by AI

Are there known risks associated with Convalescent Plasma treatment?

"Our team believes that Convalescent Plasma is moderately safe, ranking it a 2 on our safety scale due to the limited data supporting its efficacy."

Answered by AI

To what extent is the participant pool for this experiment expanding?

"Indeed, according to clinicaltrials.gov the experiment is currently hunting for participants. This investigation was first publicized on April 28th 2020 and most recently revised on June 14th 2020; requiring 30 individuals from one site to partake in it."

Answered by AI

Is recruitment for this trial still ongoing?

"Presently, per clinicaltrials.gov information, this experiment is enrolling volunteers; the original posting date was April 28th of 2020 and it was most recently revised on June 14th of the same year."

Answered by AI

Recent research and studies

The Journal of Infectious DiseasesJournal

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients with Coronavirus Disease 2019

Bradfute, Steven B, Ivy Hurwitz, Alexandra V Yingling, Chunyan Ye, Qiuying Cheng, Timothy P Noonan, Jay S Raval, et al.. 2020. “Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients with Coronavirus Disease 2019”. The Journal of Infectious Diseases. Oxford University Press (OUP). doi:10.1093/infdis/jiaa505.

clinicaltrials.govStudy

Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19

Michelle Harkins 2020. "Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04434131.